TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Concord Biotech Ltd.

CONCORDBIO on NSE · 19 Nov 2026

NIFTY 500

556.40 ▼ -0.82 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance

Filings

39 filings of CONCORDBIO since November 2024.

board outcome 13, transcript 9, presentation 8, results 4, dividend 2, acquisition 2

FiledTypeSubject
03 Nov 2026transcript
Dividend / buy-back, Guidance, Results
Concord Biotech Limited has informed the Exchange about Transcript
AI summary

Concord Biotech Limited filed the transcript of its Q2 & H1 FY27 earnings call held on October 28, 2026, under Regulation 30(6) of the SEBI LODR Regulations, 2015.

Management said Q2 FY27 revenue rose 25% year-on-year to Rs. 309.1 crore and H1 FY27 revenue rose 26% to Rs. 566.6 crore; Q2 FY27 gross margin was 76.2%, down about 400 basis points year-on-year, with management attributing this to higher raw material prices, notably solvents.

Management reported Q2 FY27 EBITDA of Rs. 104.4 crore with a 33.8% margin, and H1 FY27 PAT of Rs. 127.3 crore; the company said it has zero debt and cash of about Rs. 445 crore as of September 30, 2026.

Management said it expects to recover the margin impact over the full year and referred to a 1:1 bonus issue approved by shareholders, to take effect in the coming weeks.

Management said API business growth is expected to be slightly higher than its historical 18-19% growth rate over the next few years, with injectables, CDMO and finished formulations expected to add to growth.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
27 Oct 2026presentation
Dividend / buy-back, Legal, Results
Concord Biotech Limited has informed the Exchange about Investor Presentation
AI summary

Concord Biotech filed an investor presentation on its unaudited standalone and consolidated results for Q2 and H1 FY27 (quarter and half year ended September 30, 2026).

Consolidated revenue for Q2FY27 was Rs. 309.1 crore, up 25% from Rs. 247.1 crore in Q2FY26; H1FY27 revenue was Rs. 566.6 crore, up 26% from Rs. 451.1 crore.

Consolidated EBITDA for Q2FY27 was Rs. 104.4 crore (EBITDA margin 33.8%, down 200 bps); PAT was Rs. 69.6 crore (up 10%, PAT margin 22.5%).

Management said margins were lower on account of higher input costs and change in product mix.

Management reported the issue of bonus shares in the ratio of 1:1, the launch of dermatology division Inspira, and a USFDA inspection at the Unit II formulation facility in Ahmedabad with one minor procedural observation unrelated to GMP.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
27 Oct 2026board outcome
Dividend / buy-back, Management change, Results
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
AI summary

Board meeting held October 27, 2026 approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with limited review reports from statutory auditors BSR & Co. LLP.

Board fixed Wednesday, November 04, 2026 as record date for identifying shareholders entitled to bonus equity shares; the company will make a separate disclosure to the exchange.

Board reconstituted the Audit Committee, Nomination and Remuneration Committee, Risk Management Committee and Corporate Social Responsibility Committee, with revised composition in Annexure A.

The board meeting commenced at 3:30 P.M. and concluded at 4:45 P.M.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
23 Sep 2026bonus split
Capex, Dividend / buy-back
Concord Biotech Limited has informed the Exchange that the Board of Directors at its meeting held on September 23, 2026, have considered and approved bonus at the ratio of 1 : 1, i.e 1 Equity Shares for every 1 Equity Shares held.
AI summary

Concord Biotech's board, at its meeting on September 23, 2026, approved a 1:1 bonus issue of 1 equity share of Rs. 1/- for every 1 fully paid-up equity share of Rs. 1/- held on a record date to be decided by the board, funded by capitalising share premium, subject to shareholder approval.

The bonus would issue 10,46,16,204 equity shares, taking paid-up capital from Rs. 10,46,16,204 to Rs. 20,92,32,408; share premium available as on March 31, 2026 is Rs. 81,97,08,024.

The board also approved increasing the authorised share capital from Rs. 11,00,00,000 to Rs. 22,00,00,000 (22,00,00,000 equity shares of Rs. 1/- each), with a consequential amendment to the Memorandum of Association, subject to shareholder approval.

The company expects to credit or dispatch the bonus shares within 2 months of the board meeting, by November 22, 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 Aug 2026transcript
Capex, Guidance, Results
Concord Biotech Limited has informed the Exchange about Transcript
AI summary

Concord Biotech filed the transcript of its Q1 FY27 earnings call held on August 3, 2026, under Regulation 30(6) of the SEBI LODR Regulations, 2015.

Management said Q1 FY27 revenue was INR257 crores, up 26% year-on-year from INR204 crores; API revenue was INR219 crores (up 42%) and formulation revenue was INR39 crores (down 23%).

Management reported gross margin of 78.9% (up 100 bps), EBITDA of INR82 crores (up 34%) with a 32% margin, and PAT of INR58 crores (up 31%); cash and equivalents were above INR442 crores and Q1 capex was about INR9.5 crores.

Management said export revenue grew 46% year-on-year and that it remains confident of sustaining momentum over the coming quarters, with growth expected to be better than historical rates.

Management said existing infrastructure could support about INR3,000 crores of revenue over roughly 5 to 6 years, and Unit 3 API capacity utilisation was about 50-55%, Unit 1 about 80% and Unit 2 about 25%.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 Aug 2026presentation
Acquisition, Guidance, Results
Concord Biotech Limited has informed the Exchange about Presentation
AI summary

Concord Biotech filed the investor presentation on its unaudited standalone and consolidated results for the first quarter ended June 30, 2026 (Q1FY27).

Consolidated revenue rose 26% year-on-year to Rs. 257.5 crore (Q1FY26: Rs. 204.0 crore); PAT rose 31% to Rs. 57.7 crore (Rs. 44.1 crore); EBITDA rose 34% to Rs. 82.4 crore (Rs. 61.4 crore).

Gross profit margin was 78.9% (77.9%), EBITDA margin 32.0% (30.1%) and PAT margin 22.4% (21.6%); the presentation states EBITDA margin excluding the Injectable Facility and Stellon Biotech expenses was 37%.

Exports grew about 46% year-on-year to Rs. 121.7 crore; domestic revenue rose 12% to Rs. 135.8 crore; formulation revenue rose 42% to Rs. 218.9 crore while API revenue fell 23% to Rs. 38.6 crore.

Management (Ankur Vaid, JMD & CEO) said it expects to keep outperforming industry growth, cited USFDA approval for ANDA of Mycophenolate Mofetil and Tofacitinib tablets, and said Stellon Biotech has started commercial operations.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Jul 2026board outcome
Results
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
AI summary

Concord Biotech Limited filed the outcome of its board meeting held on July 31, 2026, which approved the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026.

The filing encloses the results along with the Limited Review Report from the statutory auditors, BSR & Co. LLP, which states nothing has come to their attention that the statement has material misstatement.

The auditors did not review two subsidiaries reviewed by another auditor, and one subsidiary's unreviewed figures show a net loss after tax of Rs. 331.73 Lakhs for the quarter.

The board meeting commenced at 3:30 P.M. and concluded at 4:35 P.M.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
20 Jun 2026acquisition
Acquisition, Capex
Concord Biotech Limited has informed the Exchange about Acquisition
AI summary

Concord Biotech Limited filed an acquisition intimation under Regulation 30 of SEBI LODR, continuing its November 13, 2025 intimation.

The Company agreed to invest Rs. 6.3 crores in cash, in one or more tranches, for subscription of 27.38% of equity share capital in FSGE Renewable Power Private Limited.

FSGE is a special purpose vehicle, incorporated August 19, 2023, to build a wind-solar hybrid power plant in Gujarat (about 6.3 MW AC wind and 6.3 MWp DC solar) for the Company's Limbasi facility; it has not commenced operations.

Equity shares are to be allotted within 60 days of the agreement date; the filing states the investment is a related party transaction at arm's length.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 Jun 2026transcript
Capex, Guidance, Results
Concord Biotech Limited has informed the Exchange about Transcript
AI summary

Concord Biotech filed the transcript of its Q4 and FY26 earnings conference call held on June 1, 2026, under Regulation 30(6) of the SEBI LODR Regulations.

Management (CEO Ankur Vaid) said FY26 was challenging, citing slower US procurement in H1, CDSCO approval issues that restricted European supplies for about 3 months, a Middle East tender on hold, and a US Veterans Affairs tender on hold; management described these as temporary and expects a normalized, stronger FY27.

CFO Raviraj Karia reported FY26 API revenue of INR 829 crores (down about 12%) and Q4 API revenue of INR 264 crores (down about 27%); total revenue degrowth was about 12% for FY26 and 24% for Q4.

Reported FY26 EBITDA was INR 367 crores at a margin of about 35%; profit after tax fell 30% to INR 260 crores; the company reported zero debt and cash of more than INR 414 crores as on March 31, 2026, with FY26 capex of INR 65 crores.

Management expects FY27 growth slightly better than the historical growth of about 18%, and said the injectable facility's expenses were about INR 38-39 crores for the full year.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 May 2026presentation
Acquisition, Capex, Guidance, Legal, Results
Concord Biotech Limited has informed the Exchange about Investor Presentation
AI summary

Concord Biotech filed its investor presentation on audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026.

Consolidated revenue was Rs. 326.1 crore in Q4FY26 (Rs. 429.9 crore in Q4FY25) and Rs. 1,054.9 crore in FY26 (Rs. 1,200.1 crore in FY25).

Consolidated PAT was Rs. 88.5 crore in Q4FY26 (Rs. 140.4 crore in Q4FY25) and Rs. 259.2 crore in FY26 (Rs. 371.6 crore in FY25).

Consolidated EBITDA was Rs. 118.5 crore in Q4FY26 (Rs. 190.4 crore in Q4FY25) and Rs. 367.4 crore in FY26 (Rs. 506.3 crore in FY25).

Management attributed FY26 challenges to timing and transition factors, including a roughly 3-month delay in CDSCO written confirmation for EU supplies, a US customer shift to staggered procurement, tariff uncertainty, Middle East headwinds and a US Veterans Affairs tender delay, and said it remains confident of an improving trend in FY 2026-27.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 May 2026board outcome
Dividend / buy-back, Management change, Results
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AI summary

Concord Biotech's board, at its meeting on May 29, 2026, approved audited standalone and consolidated results for the fourth quarter and financial year ended March 31, 2026, with an unmodified audit opinion from statutory auditor BSR & Co. LLP.

The board recommended a dividend of Rs. 7.55 per equity share (face value Re. 1) for FY 2025-26, subject to shareholder approval at the AGM, with July 24, 2026 fixed as the record date.

The board appointed Mrs. Ekta Gupta as an Additional Independent Director.

The board appointed M/s. Manubhai & Shah LLP as internal auditor and M/s. Dalwadi & Associates as cost auditor for FY 2026-27.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 May 2026dividend
Dividend / buy-back, Management change, Results
Concord Biotech Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2026, recommended Final Dividend of Rs. 7.55 per equity share.
AI summary

Concord Biotech's board approved audited standalone and consolidated results for Q4 and FY ended March 31, 2026, with an unmodified audit opinion from statutory auditor BSR & Co. LLP.

The board recommended a dividend of Rs. 7.55 per equity share (face value Re. 1) for FY 2025-26, subject to shareholder approval at the AGM, with July 24, 2026 fixed as record date.

The board appointed M/s. Manubhai & Shah LLP as Internal Auditor and M/s. Dalwadi & Associates as Cost Auditor for FY 2026-27.

The board appointed Mrs. Ekta Gupta as an Additional Independent Director.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 May 2026board outcome
Dividend / buy-back, Management change, Results
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AI summary

Concord Biotech Limited filed the outcome of its board meeting held on May 29, 2026, approving audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, with an unmodified audit opinion from statutory auditor BSR & Co. LLP.

The board recommended a dividend of Rs. 7.55 per equity share (face value Re. 1) for FY 2025-26, subject to shareholder approval at the AGM, with July 24, 2026 fixed as the record date.

The board appointed M/s. Manubhai & Shah LLP as Internal Auditor and M/s. Dalwadi & Associates as Cost Auditor for FY 2026-27.

The board appointed Mrs. Ekta Gupta as an Additional Independent Director.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
02 Apr 2026acquisition
Acquisition, Dividend / buy-back
Concord Biotech Limited has informed the Exchange about Acquisition
AI summary

Concord Biotech Limited filed an intimation under Regulation 30 of SEBI LODR regarding an acquisition, following its intimation dated November 13, 2025.

The company invested in Celliimune Biotech Private Limited, a biopharmaceutical firm incorporated on January 15, 2025, to advance DNA engineering research for cancer therapeutics.

Consideration is cash of Rs. 66,00,000 (Rs. 66 lacs) for 100% of the equity; the acquisition was completed on April 02, 2026.

Celliimune has nil turnover; the filing states the deal is a related party transaction in which promoter/promoter group entities are interested, done at arm's length.

No governmental or regulatory approvals are stated as required.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
18 Feb 2026transcript
Capex, Guidance, Legal, Results
Concord Biotech Limited has informed the Exchange about Transcript
AI summary

Concord Biotech filed the transcript of its Q3 and nine months FY26 earnings call held on February 12, 2026, under Regulation 30(6) of the SEBI LODR Regulations.

Management said Q3 FY26 revenue was INR 278 crores (up 14% year-on-year) and nine-month FY26 revenue was INR 729 crores (down 5% from INR 770 crores); Q3 EBITDA was INR 99 crores with a 35.6% margin, or about 40% excluding injectables start-up and US subsidiary costs.

Q3 profit after tax was INR 64 crores versus INR 76 crores a year earlier, which management attributed partly to a one-time INR 3 crore labour code provision.

Management said FY26 is expected to remain below historical averages, while it anticipates FY27 and beyond will normalise toward historical growth, and that Q4 will be stronger.

Management said the WHO GMP-certified injectable facility has a peak revenue potential of about INR 600 crores, and that a CDMO product is commercialised in the US.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Feb 2026presentation
Capex, Management change, Results
Concord Biotech Limited has informed the Exchange about Investor Presentation
AI summary

Investor presentation on unaudited standalone and consolidated results for Q3 and nine months ended December 31, 2025 (Q3FY26 and 9MFY26).

Consolidated revenue was Rs. 277.8 crore in Q3FY26 vs Rs. 244.2 crore in Q3FY25; nine-month revenue was Rs. 728.8 crore vs Rs. 770.2 crore.

Consolidated PAT was Rs. 63.7 crore in Q3FY26 vs Rs. 75.9 crore in Q3FY25; nine-month PAT was Rs. 170.8 crore vs Rs. 231.3 crore.

Management said normalized EBITDA margin was about 40% for Q3 and 9MFY26, with reported EBITDA margin of 35.6% in Q3FY26 and 34.1% in 9MFY26, impacted by commercialization expenses for the new injectable facility and Stellon Biotech setup costs.

Management highlighted WHO-GMP certification for the injectable facility (unit 4), setup of US subsidiary Stellon Biotech Inc., and appointment of Mr. Raviraj Karia as Chief Financial Officer.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Feb 2026board outcome
Management change, Results
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
AI summary

Board of Concord Biotech Limited approved unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, with Limited Review Reports (unmodified opinion) from statutory auditors BSR & Co. LLP.

The Board appointed Mr. Paritosh Trivedi as Company Secretary, Compliance Officer and Nodal Officer with effect from February 11, 2026.

Mr. Trivedi is an Associate Member of the Institute of Company Secretaries of India with around 5 years of experience in corporate compliance and secretarial functions; he holds NIL shares in the company and is not related to any director.

The Board meeting commenced at 5:00 P.M. and concluded at 6:22 P.M. on February 11, 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
18 Dec 2025board outcome
Management change
Concord Biotech Limited has informed the Exchange regarding Board meeting held on December 18, 2025.
AI summary

Concord Biotech Limited filed the outcome of its board meeting held on December 18, 2025 (meeting ran from 12:10 PM to 12:50 PM).

The board, on recommendation of the Nomination and Remuneration Committee and Audit Committee, approved the appointment of Mr. Raviraj Karia as Chief Financial Officer and Key Managerial Personnel, effective December 18, 2025.

Mr. Raviraj Karia is a Chartered Accountant with more than 23 years of experience in pharmaceuticals, healthcare, clinical research, logistics and private equity.

He is not related to any Director of the company and holds NIL shares in the company.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 Nov 2025transcript
Acquisition, Capex, Guidance, Legal, Results
Concord Biotech Limited has informed the Exchange about Transcript
AI summary

Concord Biotech filed the transcript of its Q2 and H1 FY26 earnings conference call held on November 14, 2025, under Regulation 30(6) of the SEBI LODR; the transcript and audio are on the company website.

Management said Q2 FY26 revenue was Rs. 247 crores (down about 20% year-on-year, up 21% quarter-on-quarter) and H1 FY26 revenue was Rs. 451 crores, citing CDSCO written confirmation delays, a deferred Middle East government tender and a shift in US procurement patterns due to tariff uncertainty.

Management said Q2 FY26 EBITDA was Rs. 88 crores at a 36% margin (41% excluding start-up costs of the new Valthera injectables facility), and Q2 PAT was Rs. 63 crores with H1 PAT of Rs. 107 crores.

Management said it expects a stronger H2 FY26 and that the injectables facility will contribute positively to margins as utilisation rises.

Management highlighted USFDA approval for Teriflunomide Tablets, the incorporation of Stellon Biotech Inc. (US) and Concord Lifegen Limited, and an investment in Cellimmune Biotech Limited.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Nov 2025presentation
Legal, Results
Concord Biotech Limited has informed the Exchange about Investor Presentation
AI summary

Investor presentation filed for Q2 and H1 FY26 results (quarter and half year ended September 30, 2025).

Consolidated revenue for Q2FY26 was Rs. 526.0 crore versus Rs. 310.2 crore in Q2FY25; H1FY26 revenue was Rs. 451.1 crore versus Rs. 247.1 crore in H1FY25 (as printed in the slides).

Consolidated EBITDA for Q2FY26 was Rs. 149.9 crore versus Rs. 88.5 crore in Q2FY25; PAT for Q2FY26 was Rs. 107.1 crore versus Rs. 63.1 crore.

Management said revenue was impacted by a delay in renewal of CDSCO Written Confirmation for EU supplies, which it says received approval on November 4, 2025, and by delayed US supplies due to tariff uncertainty and a Middle East tender put on hold.

Management reported US FDA Establishment Inspection Report for the Dholka facility, and successful EU GMP inspections at Dholka and Limbasi, and stated that unit economics are on an improving trend.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Nov 2025board outcome
Acquisition, Capex, Legal, Results
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
AI summary

Concord Biotech Limited's board on November 13, 2025 approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2025; Q2 standalone revenue from operations was Rs. 24,705.75 lakhs and standalone profit after tax was Rs. 6,289.63 lakhs (vs Rs. 9,869.94 lakhs in Q2 FY25).

Half-year (six months ended September 30, 2025) standalone revenue from operations was Rs. 45,104.51 lakhs and profit after tax was Rs. 10,546.19 lakhs, against Rs. 52,598.29 lakhs and Rs. 15,693.80 lakhs in the prior-year half.

The board approved a related party transaction to acquire 100% equity share capital of Celliimune Biotech Private Limited; the necessary disclosure will be made upon completion of the acquisition.

The board approved an investment of up to Rs. 10 crores in a captive hybrid solar power project for the Limbasi plant.

The statutory auditor, BSR & Co. LLP, issued a limited review report with an unmodified opinion on the standalone results.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Nov 2025results
Acquisition, Capex, Results
1. Approval of Q2 FY26 Financial results 2. Upon recommendation of Audit committee, board approved to Invest by way of acquiring 100 % equity share capital of M/s Celliimune Biotech Private Limited. 3. Upon recommendation of Audit committee
AI summary

Concord Biotech Limited filed its unaudited standalone and consolidated results for the quarter and half year ended September 30, 2025, approved by the Board on November 13, 2025, with a limited review report from BSR & Co. LLP (unmodified).

Standalone revenue from operations was Rs. 24,705.75 lakhs for the quarter ended September 30, 2025, versus Rs. 31,018.12 lakhs a year earlier; profit after tax was Rs. 6,289.63 lakhs versus Rs. 9,869.94 lakhs.

For the half year ended September 30, 2025, standalone revenue from operations was Rs. 45,104.51 lakhs (Rs. 52,598.29 lakhs a year earlier) and profit after tax was Rs. 10,546.19 lakhs (Rs. 15,693.80 lakhs).

Basic and diluted EPS for the quarter was Rs. 6.01 (not annualised), versus Rs. 9.43 a year earlier.

The Board also approved a related party transaction to acquire 100% equity of Celliimune Biotech Private Limited, and an investment of up to Rs. 10 crores in a captive hybrid solar power project for the Limbasi plant.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Nov 2025board outcome
Acquisition, Capex, Results
Concord Biotech Limited has informed the Exchange regarding Board meeting held on November 13, 2025.
AI summary

Concord Biotech Limited's board on November 13, 2025 approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2025, with a limited review report from BSR & Co. LLP (unmodified opinion).

Standalone revenue from operations for Q2 FY26 was Rs. 24,705.75 lakhs, versus Rs. 31,018.12 lakhs in Q2 FY25; profit after tax was Rs. 6,289.63 lakhs versus Rs. 9,869.94 lakhs.

Standalone revenue from operations for the six months ended September 30, 2025 was Rs. 45,104.51 lakhs, versus Rs. 52,598.29 lakhs a year earlier; profit after tax was Rs. 10,546.19 lakhs versus Rs. 15,693.80 lakhs.

The board approved acquiring 100% equity share capital of Celliimune Biotech Private Limited as a related party transaction, with disclosure to follow on completion.

The board approved investment of up to Rs. 10 crores in a captive hybrid solar power project for its Limbasi plant.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
18 Aug 2025transcript
Acquisition, Capex, Legal, Results
Concord Biotech Limited has informed the Exchange about Transcript
AI summary

Concord Biotech filed the transcript of its Q1 FY26 earnings conference call held on August 11, 2025, under Regulation 30(6) of the SEBI LODR, and uploaded it to its website.

Management reported Q1 FY26 revenue of INR 204 crores, down 5% from INR 216 crores a year earlier; API revenue of INR 153.8 crores (down 10%) and formulation revenue of INR 50.2 crores (up 12%).

EBITDA was INR 61 crores with a margin of 30.1% (37.7% a year earlier); management attributed the decline mainly to commercialisation costs of the new Valthera injectable facility, with margin excluding these costs at about 37%.

Profit after tax was INR 44 crores (INR 60 crores a year earlier), a PAT margin of 21.6%.

Management said US FDA, EU GMP and Russian GMP inspections were cleared at the Dholka API facility and that Stellon Biotech, Inc. (US) and Concord Lifegen Limited (India) subsidiaries were incorporated.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
10 Aug 2025presentation
Acquisition, Guidance, Results
Concord Biotech Limited has informed the Exchange about Investor Presentation
AI summary

Concord Biotech Limited filed its investor presentation on financial results for the first quarter ended June 30, 2025 (Q1FY26).

Consolidated revenue was Rs. 204.0 crore in Q1FY26 versus Rs. 215.8 crore in Q1FY25, down 5%, which management attributed to lumpiness in customer procurement patterns.

Consolidated EBITDA was Rs. 61.4 crore (EBITDA margin 30.1%) versus Rs. 81.3 crore (37.7%) a year earlier; management said this was impacted by expenses for commercialising the new injectable facility at Valthera, and that margin excluding those new-facility expenses was 37%.

Consolidated PAT was Rs. 44.1 crore (PAT margin 21.6%) versus Rs. 59.6 crore (27.6%) in Q1FY25.

Management said it acquired a 75% stake in Stellon Biotech (US), incorporated Concord Lifegen Limited as a wholly owned subsidiary, and remains optimistic of maintaining its growth trajectory for FY26 and beyond.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
08 Aug 2025board outcome
Dividend / buy-back, Results
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AI summary

Concord Biotech Limited filed the outcome of its board meeting held on August 8, 2025, approving unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with a limited review report from BSR & Co. LLP (unmodified opinion).

Standalone revenue from operations for Q1 FY26 was Rs. 20,398.76 lakhs, against Rs. 21,580.17 lakhs in the quarter ended June 30, 2024; profit after tax was Rs. 4,256.55 lakhs, against Rs. 5,823.86 lakhs a year earlier.

Basic and diluted EPS (not annualised) was Rs. 4.07 for the quarter.

The board fixed September 3, 2025 as the record date for a dividend of Rs. 10.70 per equity share (face value Re. 1) for FY 2024-25.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Jun 2025transcript
Capex, Dividend / buy-back, Guidance, Legal, Results
Concord Biotech Limited has informed the Exchange about Transcript
AI summary

Concord Biotech filed the transcript of its Q4 and FY25 earnings conference call held on May 30, 2025, with the audio recording also uploaded to its website.

Management said Q4 FY25 revenue grew 35% to INR 430 crores and FY25 revenue was INR 1,200 crores (up 18%); Q4 PAT was INR 140 crores (up 48%) and FY25 PAT was INR 372 crores (up 21%).

Management said Q4 FY25 operating EBITDA was INR 190 crores (44.3% margin) and FY25 operating EBITDA was INR 506 crores (42.2% margin).

Management recommended a final dividend of INR 10.7 per share for FY25, subject to shareholder approval.

Management said the injectable facility at Valthera was commissioned, with revenue contribution expected in FY26 and full ramp-up over FY27 and FY28.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 May 2025presentation
Acquisition, Results
Concord Biotech Limited has informed the Exchange about Investor Presentation
AI summary

Concord Biotech filed its investor presentation for the quarter and year ended March 31, 2025.

Consolidated revenue for Q4FY25 was Rs. 429.9 crore, up 35% from Rs. 319.0 crore in Q4FY24; FY25 revenue was Rs. 1,200.1 crore, up 18% from Rs. 1,016.9 crore.

Consolidated PAT for Q4FY25 was Rs. 140.4 crore, up 48% from Rs. 95.0 crore; FY25 PAT was Rs. 371.6 crore, up 21% from Rs. 308.1 crore.

Q4FY25 EBITDA was Rs. 190.4 crore, up 42% from Rs. 134.3 crore; FY25 EBITDA was Rs. 506.3 crore, up 17% from Rs. 431.5 crore.

The company reported receiving final USFDA ANDA approval for Teriflunomide Tablets (7 mg & 14 mg) and strategic investments in Palvella Therapeutics Inc. and CleanMax.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 May 2025board outcome
Dividend / buy-back, Legal, Management change, Results
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
AI summary

Board of Concord Biotech Limited approved and took on record the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2025, with unmodified audit opinion from BSR & Co. LLP.

The Board recommended a dividend of Rs. 10.70 per equity share (face value Re. 1) for FY 2024-25, subject to shareholder approval at the ensuing AGM.

Ms. Hina Patel (ACS A56541) was appointed Company Secretary and Compliance Officer (Key Managerial Personnel) with effect from May 30, 2025.

The Board approved appointment of Ashish Shah & Associates as Secretarial Auditor for FY 2025-26 to FY 2029-30, Manubhai & Shah LLP as Internal Auditor for FY 2025-26, and Dalwadi & Associates as Cost Auditor for FY 2025-26, subject to shareholder approval where required.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 May 2025board outcome
Dividend / buy-back, Management change, Results
Concord Biotech Limited has informed the Exchange regarding Board meeting held on May 29, 2025.
AI summary

Board of Concord Biotech Limited approved and took on record the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2025, with unmodified audit opinion from BSR & Co. LLP.

The Board recommended a dividend of Rs. 10.70 per equity share (face value Re. 1) for FY 2024-25, subject to shareholder approval at the ensuing AGM.

Ms. Hina Patel (ACS A56541) was appointed Company Secretary and Compliance Officer (Key Managerial Personnel) with effect from May 30, 2025.

The Board approved appointment of Ashish Shah & Associates as Secretarial Auditor for FY 2025-26 to 2029-30, Manubhai & Shah LLP as Internal Auditor for FY 2025-26, and Dalwadi & Associates as Cost Auditor for FY 2025-26, subject to shareholder approval where required.

The board meeting commenced at 5.00 P.M. and concluded at 6:30 P.M.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 May 2025results
Dividend / buy-back, Legal, Management change, Results
To approve Audited Financial Results for the quarter and Financial Year ended on March 31, 2025 and to approve other agendas.
AI summary

Concord Biotech Limited's board approved and took on record the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2025, on May 29, 2025; statutory auditors BSR & Co. LLP issued unmodified audit opinions.

The board recommended a dividend of Rs. 10.70 per equity share (face value Re. 1) for FY 2024-25, subject to shareholder approval at the ensuing AGM.

Ms. Hina Patel (ACS A56541), already an employee, was appointed Company Secretary and Compliance Officer (KMP) with effect from May 30, 2025.

The board approved appointment of Ashish Shah & Associates as Secretarial Auditor for FY 2025-26 to 2029-30, Manubhai & Shah LLP as Internal Auditor for FY 2025-26, and Dalwadi & Associates as Cost Auditor for FY 2025-26.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 May 2025dividend
Dividend / buy-back, Legal, Management change, Results
Concord Biotech Limited has informed the Exchange that Board of Directors at its meeting held on May 29, 2025, recommended Final Dividend of 10.70 per equity share.
AI summary

Concord Biotech Limited filed the outcome of its board meeting held on May 29, 2025, approving audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2025, with unmodified audit opinions from BSR & Co. LLP.

The board recommended a dividend of Rs. 10.70 per equity share (face value Re. 1) for FY 2024-25, subject to shareholder approval at the ensuing AGM.

Ms. Hina Patel was appointed Company Secretary and Compliance Officer (Key Managerial Personnel) with effect from May 30, 2025.

The board approved appointment of Ashish Shah & Associates as Secretarial Auditor for FY 2025-26 to FY 2029-30, Manubhai & Shah LLP as Internal Auditor for FY 2025-26, and Dalwadi & Associates as Cost Auditor for FY 2025-26.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Mar 2025board outcome
Acquisition, Capex
Concord Biotech Limited has informed the Exchange regarding Outcome of Board Meeting held on March 04, 2025.
AI summary

Board of Concord Biotech approved on March 4, 2025 an investment of Rs. 6,09,58,836 through subscription to a rights issue of shares in Clean Max Everglades Pvt Ltd.

The funds are to set up a hybrid renewable energy plant in Gujarat (6.6 MW wind and 3.3 MWp DC solar) for the company's Dholka plant.

The company already holds 26% equity in Clean Max, which is an associate; the investment is classed as a related party transaction at arm's length.

Equity shares against the current investment are to be allotted within 30 days; consideration is cash.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
21 Feb 2025transcript
Acquisition, Capex, Guidance, Results
Concord Biotech Limited has informed the Exchange about Transcript
AI summary

Concord Biotech filed transcript of its Q3 FY25 and nine months FY25 earnings conference call held on February 14, 2025, under Regulation 30(6) of SEBI LODR; transcript and audio are on the company website.

Management said Q3 FY25 revenue from operations was INR 244 crores vs INR 240 crores in Q3 FY24 (1% growth); EBITDA INR 98 crores (40.1% margin); PAT INR 76 crores (31.1% margin).

For nine months FY25, revenue was INR 770 crores vs INR 698 crores (10% growth); formulation revenue rose 42% to INR 192 crores; PAT was INR 231 crores vs INR 213 crores.

Management said the Q3 slowdown reflected customer procurement phasing and calendar-year closures of global clients, with orders shifting to Q4; it reaffirmed long-term guidance of 25% revenue CAGR over five years and 40%-43% long-term EBITDA margin.

Management said the company made a $1 million investment in compulsory convertible notes of Palvella Therapeutics and agreed to acquire a 26% equity stake in CleanMax, which supplies renewable power to the Dholka plant; the injectable plant was scheduled to begin commercial production in the current quarter.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Feb 2025presentation
Guidance, Results
Concord Biotech Limited has informed the Exchange about Investor Presentation
AI summary

Investor presentation for the third quarter and nine months ended December 31, 2024, filed under Regulation 30 of the SEBI LODR Regulations.

Q3FY25 consolidated revenue was Rs. 244.2 crs (up 1% YoY from Rs. 240.8 crs); 9MFY25 revenue was Rs. 770.2 crs (up 10% from Rs. 698.0 crs).

Q3FY25 EBITDA was Rs. 98.0 crs (down 8% YoY) with EBITDA margin of 40.1%; Q3FY25 PAT was Rs. 75.9 crs (down 2% YoY) with PAT margin of 31.1%.

Management (Ankur Vaid, Joint MD & CEO) said Q3FY25 API revenue grew 3% YoY, impacted by lumpy customer procurement and some revenue spilling into the following quarter.

Management said it remains optimistic about growth in both API and formulation segments, targets a 25% CAGR over the next five years, and is exploring CDMO/CMO opportunities.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Feb 2025results
Results
Integrated filling of financial results for the Third quarter and nine months period ended on 31st December, 2024
AI summary

Concord Biotech Limited's board approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, on February 13, 2025, with limited review reports (unmodified) from statutory auditor BSR & Co. LLP.

Standalone revenue from operations for Q3 FY25 (quarter ended Dec 31, 2024) was Rs. 24,422.02 lakhs versus Rs. 24,079.65 lakhs in Q3 FY24; standalone profit after tax was Rs. 7,408.88 lakhs versus Rs. 7,055.30 lakhs.

Standalone revenue from operations for the nine months ended Dec 31, 2024 was Rs. 77,020.31 lakhs versus Rs. 69,796.98 lakhs in the prior-year period; profit after tax was Rs. 23,102.68 lakhs versus Rs. 20,751.75 lakhs.

Basic and diluted EPS for the quarter was Rs. 7.08 (not annualised), against Rs. 7.13 in the corresponding quarter last year.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Feb 2025results
Results
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
AI summary

Concord Biotech Limited's board approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, on February 13, 2025.

Q3 FY25 standalone revenue from operations was Rs. 24,422.02 lakhs versus Rs. 24,079.65 lakhs in Q3 FY24 and Rs. 31,018.12 lakhs in Q2 FY25 (quarter ended September 30, 2024).

Q3 FY25 standalone profit after tax was Rs. 7,408.88 lakhs versus Rs. 7,055.30 lakhs in Q3 FY24.

Nine-month standalone revenue from operations was Rs. 77,020.31 lakhs and profit after tax was Rs. 23,102.68 lakhs, versus Rs. 69,796.98 lakhs and Rs. 20,751.75 lakhs in the prior-year nine months.

The Limited Review Reports issued by BSR & Co. LLP carry unmodified opinions.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Feb 2025board outcome
Results
Concord Biotech Limited has informed the Exchange regarding Outcome of Board Meeting held on February 13, 2025.
AI summary

Concord Biotech Limited's board approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, on February 13, 2025.

Standalone revenue from operations for Q3 FY25 (quarter ended Dec 31, 2024) was Rs. 24,422.02 lakhs, against Rs. 31,018.12 lakhs in the quarter ended Sept 30, 2024 and Rs. 24,079.65 lakhs in the quarter ended Dec 31, 2023.

Standalone net profit after tax for Q3 FY25 was Rs. 7,408.88 lakhs, against Rs. 9,869.94 lakhs in the previous quarter and Rs. 7,055.30 lakhs in the corresponding quarter last year.

For the nine months ended Dec 31, 2024, standalone revenue from operations was Rs. 77,020.31 lakhs and profit after tax was Rs. 23,102.68 lakhs; basic and diluted EPS for the nine months was Rs. 22.08 (not annualised).

The Statutory Auditor, BSR & Co. LLP, issued a limited review report with an unmodified opinion.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 Nov 2024transcript
Capex, Guidance, Results
Concord Biotech Limited has informed the Exchange about Transcript
AI summary

Concord Biotech filed the transcript of its Q2 and H1 FY25 earnings conference call held on November 12, 2024, per Regulation 30(6) of the SEBI LODR.

Management reported Q2 FY25 revenue of INR 310 crores (vs INR 262 crores in Q2 FY24) and PAT of INR 99 crores (vs INR 84 crores), both up 18% year-on-year.

Management reported H1 FY25 revenue of INR 526 crores (vs INR 457 crores in H1 FY24), up 15%, and H1 EBITDA of INR 218 crores, up 14%.

Management said formulation revenue in Q2 rose 125% to INR 80 crores, while API revenue was INR 230 crores vs INR 226 crores, muted because inter-unit API sales to formulations are excluded.

Management said the company had cash, investments and bank balances of INR 284 crores as on September 30, 2024 and is a zero-debt company.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy

The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in